OVERALL SURVIVAL WITH DEXAMETHASONE IN PHASE III MULTIPLE MYELOMA TRIALS AFTER ADJUSTMENT FOR CROSS-OVER TO LENALIDOMIDE

被引：0

作者：

Morgan, J. ^{[1
,2
]}

Ishak, K. ^{[3
]}

Deniz, B. ^{[3
]}

Drayson, T. ^{[4
]}

Dimopoulos, M. ^{[5
]}

Weber, M. ^{[6
]}

Augustson, M. ^{[7
]}

Child, J. ^{[8
]}

Knight, R. ^{[9
]}

Begum, G. ^{[10
]}

Dunn, A. ^{[10
]}

Shearer, A. ^{[11
]}

Caro, J. ^{[3
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Surrey, England

[2] Inst Canc Res, Surrey, England

[3] United BioSource Corp, Montreal, PQ, Canada

[4] Univ Birmingham, Birmingham, W Midlands, England

[5] Univ Athens, Sch Med, GR-11527 Athens, Greece

[6] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[8] Univ Leeds, Leeds, W Yorkshire, England

[9] Celgene, Summit, NJ USA

[10] Warwick Med Sch, Coventry, W Midlands, England

[11] Celgene, London, England

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0441

引用

页码：178 / 178

页数：1